Abrocitinib for the treatment of atopic dermatitis

References

• Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76:736–744.
   PubMed Web of Science ®Google Scholar
• Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78:S53–S62.
   PubMed Web of Science ®Google Scholar
• Ciechanowicz P, Rakowska A, Sikora M, et al. JAK-inhibitors in dermatology: current evidence and future applications. J Dermatolog Treat. 2019;30:648–658.
   PubMed Web of Science ®Google Scholar
• Fourzali K, Yosipovitch G. Safety considerations when using drugs to treat pruritus. Expert Opin Drug Saf. 2020;19:467–477.
   PubMed Web of Science ®Google Scholar
• Montilla AM, Gómez-García F, Gómez-Arias PJ, et al. Scoping review on the use of drugs targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatol Ther (Heidelb). 2019;9:655–683.
   PubMed Web of Science ®Google Scholar
• Gündüz Ö. JAK/STAT pathway modulation: does it work in dermatology? Dermatol Ther. 2019;32. DOI:10.1111/dth.12903
   PubMed Web of Science ®Google Scholar
• Palanivel JA, Macbeth AE, Chetty NC, et al. An insight into JAK-STAT signalling in dermatology. Clin Exp Dermatol. 2019;39:513–518.
   Google Scholar
• Welsch K, Holstein J, Laurence A, et al. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 2017;47:1096–1107.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40:84–92.
   PubMed Web of Science ®Google Scholar
• Egawa G, Weninger W. Pathogenesis of atopic dermatitis: A short review. Ginhoux F, editor. Cogent Biol. 2015;1. DOI:10.1080/23312025.2015.1103459
   Web of Science ®Google Scholar
• Kim BE, Leung DYM. Significance of skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol Res. Korean Academy of Asthma, Allergy and Clinical Immunology. 2018;10:207–215.
   PubMed Web of Science ®Google Scholar
• Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138(350–358.e1):350–358.e1.
   PubMedGoogle Scholar
• Schleimer RP, Berdnikovs S. Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases. J Allergy Clin Immunol. 2017;139:1752–1761.
   PubMed Web of Science ®Google Scholar
• Vazquez ML, Kaila N, Strohbach JW, et al. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. J Med Chem. 2018;61:1130–1152.
   PubMed Web of Science ®Google Scholar
• Schmieder GJ, Draelos ZD, Pariser DM, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. Br J Dermatol. 2018;179:54–62.
   PubMed Web of Science ®Google Scholar
• Peeva E, Hodge MR, Kieras E, et al. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study. Br J Clin Pharmacol. 2018;84:1776–1788.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: A phase 2 randomized clinical trial. JAMA Dermatol. 2019;155:1371–1379.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396:255–266.
   PubMed Web of Science ®Google Scholar
• Simpson E, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase 3 JADE MONO-1 study. Revolutionizing Atopic Dermat Virtual Conf. Chicago, Illinois; 2020.
   Google Scholar
• Silverberg JI, Simpson EL, Thyssen JP, et al., Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2020;156(8):863.
   Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase 3 JADE MONO-2 study. Revolutionizing Atopic Dermat Virtual Conf. Chicago, Illinois; 2020.
   Google Scholar
• Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. Elsevier Ltd. 2015;36:422–439.
   PubMed Web of Science ®Google Scholar
• He H, Guttman-Yassky E. JAK INHIBITORS FOR ATOPIC DERMATITIS: AN UPDATE. Am J Clin Dermatol. 2019;20:181–192.
   PubMed Web of Science ®Google Scholar
• Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol. 2016;32:29–33.
   PubMed Web of Science ®Google Scholar
• Samadi A, Ahmad Nasrollahi S, Hashemi A, et al. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. J Dermatolog Treat. Taylor and Francis Ltd. 2017;28:476–483.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–328.
   PubMed Web of Science ®Google Scholar
• Mobasher P, Heydari Seradj M, Raffi J, et al. Oral small molecules for the treatment of atopic dermatitis: a systematic review. J Dermatolog Treat. 2019;30:550–557.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145:877–884.
   PubMed Web of Science ®Google Scholar
• Craig Venter J, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291(80):1304–1351. .
   PubMedGoogle Scholar
• Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science. 2002;298(80):1912–1934. .
   PubMedGoogle Scholar
• Tsygankov AY. Non-receptor protein kinases. Front Biosci. 2003;8:635.
   Web of Science ®Google Scholar
• Gocek E, Moulas AN, Studzinski GP. Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells. Crit Rev Clin Lab Sci. 2014;51:125–137.
   PubMed Web of Science ®Google Scholar
• Raivola J, Haikarainen T, Silvennoinen O. Characterization of JAK1 pseudokinase domain in cytokine signaling. Cancers (Basel). 2019;12:78.
   Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273–287.
   PubMed Web of Science ®Google Scholar
• Firmbach-Kraft I, Byers M, Shows T, et al. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene. 1990;5:1329–1336.
   PubMed Web of Science ®Google Scholar
• Pritchard MA, Baker E, Callen DF, et al. Two members of the JAK family of protein tyrosine kinases map to chromosomes 1p31.3 and 9p24. Mamm Genome. 1992;3:36–38.
   PubMed Web of Science ®Google Scholar
• Riedy MC, Dutra AS, Blake TB, et al. Genomic sequence, organization, and chromosomal localization of human JAK3. Genomics. 1996;37:57–61.
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Saharinen P, Pesu M, et al. The Janus kinases (Jaks). Genome Biol. 2004;5:253.
   PubMed Web of Science ®Google Scholar
• Rane SG, Reddy EP. JAK3: A novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene. 1994;9:2415–2423.
   PubMed Web of Science ®Google Scholar
• Gooderham M. Small molecules: an overview of emerging therapeutic options in the treatment of psoriasis. Skin Ther. 2013;18:1–4.
   PubMedGoogle Scholar
• Müller M, Briscoe J, Laxton C, et al. The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction. Nature. 1993;366:129–135.
   PubMed Web of Science ®Google Scholar
• Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014;23:1067–1077.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Hong HCH, Eshtiaghi P, et al. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78:S28–S36.
   PubMed Web of Science ®Google Scholar
• Soria A, Du-Thanh A, Seneschal J, et al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with Dupilumab. JAMA Dermatol. 2019;155:1312–1315.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183:242–255.
   PubMed Web of Science ®Google Scholar
• Jarocha DJ, Gadue P, Tong W, et al. Janus Kinase (Jak) 1 inhibition affects both megakaryopoiesis and thrombopoiesis. Blood. 2018;132:2559.
   Web of Science ®Google Scholar